“
TL;DR
A small real-world study found greater mean weight loss (15.9% vs 9.0%) with phenotype-guided medication selection compared with standard care, though this approach awaits confirmation in randomised trials.
Reviews in Endocrine & Metabolic Disorders · 2 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A small real-world study found greater mean weight loss (15.9% vs 9.0%) with phenotype-guided medication selection compared with standard care, though this approach awaits confirmation in randomised trials.
This narrative review synthesises clinical data on individualised prescription of obesity pharmacotherapies in adults, covering available agents (orlistat, phentermine, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide) with their mechanisms, efficacy, and adverse effect profiles. The review highlights that no reliable method currently exists for predicting which medication will be most effective for an individual prior to treatment initiation. Key limitations include the absence of randomised trials testing phenotype-guided approaches and very few head-to-head comparisons between available agents.